Table 1.
Baseline characteristics of the PS matched cohorts
| Variable | PS matched cohorts | |||
|---|---|---|---|---|
| LAA-amputation | z-difference | Std. mean difference | ||
| No (n = 243) | Yes (n = 243) | |||
| NYHA (%) | 0.24 | – | ||
| NYHA I | 75 (29.8) | 68 (27.0) | ||
| NYHA II | 103 (40.9) | 113 (44.8) | ||
| NYHA III | 71 (28.2) | 68 (27.0) | ||
| NYHA IV | 3 (1.2) | 3 (1.2) | ||
| Ejection fraction (SD) | 58.2 (9.1) | 57.6 (9.9) | − 0.68 | 0.06 |
| DVT (%) | 4 (1.6) | 5 (2.0) | 0.34 | 0.03 |
| Beta-blocker (%) | 179 (71.0) | 170 (67.5) | − 0.87 | 0.08 |
| Calcium antagonist (%) | 64 (25.4) | 66 (26.2) | 0.20 | 0.02 |
| EuroSCORE2 (IQR) | 1.2 (1.1) | 1.3 (1.2) | 0.28 | 0.03 |
| CHA2DS2-VASc-score (SD) | 3.1 (1.4) | 3.1 (1.3) | 0.13 | 0.01 |
| Age (SD) | 69.6 (8.1) | 69.1 (7.6) | − 0.70 | 0.06 |
| BMI (SD) | 29.1 (4.3) | 29.1 (4.3) | − 0.05 | 0.01 |
| TSH (µU/ml) (IQR) | 1.1 (1.0) | 1.1 (1.0) | 0.55 | 0.05 |
| ASA classification (%) | 0.30 | – | ||
| Normal healthy patient | 13 (5.2) | 13 (5.2) | ||
| Patient with mild systemic disease | 21 (8.3) | 20 (7.9) | ||
| Patient with severe systemic disease | 207 (82.1) | 206 (81.7) | ||
| Patient with severe systemic disease that is a constant threat to life | 11 (4.4) | 13 (5.2) | ||
| CCS (%) | − 0.39 | – | ||
| No | 70 (27.8) | 71 (28.2) | ||
| CCS I | 80 (31.7) | 85 (33.7) | ||
| CCS II | 58 (23.0) | 56 (22.2) | ||
| CCS III | 41 (16.3) | 34 (13.5) | ||
| CCS IV | 3 (1.2) | 6 (2.4) | ||
| Female (%) | 48 (19.0) | 54 (21.4) | 0.67 | 0.06 |
| Myocardial infarction (%) | 0.29 | – | ||
| Longer than 90 days | 32 (12.7) | 31 (12.3) | ||
| 21–90 days | 6 (2.4) | 6 (2.4) | ||
| 7–21 days | 8 (3.2) | 7 (2.8) | ||
| 48 h–7 days | 2 (0.8) | 3 (1.2) | ||
| 24–48 h | 2 (0.8) | 4 (1.6) | ||
| 6–24 h | 1 (0.4) | 1 (0.4) | ||
| 0–6 h | 0 (0.0) | 1 (0.4) | ||
| Arterial hypertension (%) | 226 (89.7) | 223 (88.5) | − 0.43 | 0.04 |
| Diabetes mellitus type 2 (%) | 100 (39.7) | 105 (41.7) | 0.45 | 0.04 |
| Pulmonary disease (%) | 16 (6.3) | 20 (7.9) | 0.70 | 0.06 |
| Hyperlipidemia (%) | 239 (94.8) | 234 (92.9) | − 0.94 | 0.08 |
| Smoking (%) | 93 (36.9) | 101 (40.1) | 0.73 | 0.07 |
| Not used for PSM | ||||
| Coronary artery disease (%) | 2.8 ± 0.5 | 2.9 ± 0.3 | 0.13 | |
| 1-CAD | 9 (3.7) | 0 (0) | ||
| 2-CAD | 36 (14.8) | 27 (11.1) | ||
| 3-CAD | 198 (81.5) | 216 (88.9) | ||
| Operation time (min) | 196.4 ± 46.5 | 199.5 ± 37.8 | 0.36 | |
ASA American Society of Anesthesiologists, BMI body mass index, CAD coronary artery disease, DVT deep vein thrombosis, IQR interquartile range, NYHA New York Heart Association, PSM propensity score matching, TSH thyroid stimulating hormone